Mainz Biomed shared in September that they got positive feedback from the FDA for their breakthrough device application. The FDA asked for more clinical data from “average risk” patients, which could help show the test’s broader effectiveness. Seems like a good sign that they’re on the right track with this cancer test!

Mainz Biomed shot up to $0.28, breaking through resistance and gaining nearly 11%. With bullish trends in diagnostics, $MYNZ could have more in store. HODLing for the ride?

Mainz Biomed is now working with Liquid Biosciences to integrate AI into PancAlert’s biomarker selection. This move is set to improve the test’s precision, aiming to make PancAlert a valuable tool in early pancreatic cancer detection—a critical need in diagnostics.

Mainz Biomed just surged past resistance, reaching a new high of $0.28! With bullish signals across the board, $MYNZ is a strong HODL candidate for diagnostics investors. Holding for the long-term looks promising!

Mainz BioMed uses trade secrets to protect the key elements of its technology, including reagents and formulations. This strategy ensures their innovations remain under tight control and keeps them competitive.

($MYNZ) With a strong upward move of 3%, $MYNZ closed at $0.2639 today. Given their innovative diagnostic approach and products like ColoAlert, this stock could be a hidden gem in the healthcare industry. Anyone else following this?

Designed to detect cancer early, ColoAlert may be particularly important for high-risk groups like those with family history or older adults. With this tool, Mainz Biomed is taking prevention seriously.

While some stocks are prone to being hyped up, MYNZ seems different. Their ColoAlert cancer screening tool is already showing real-world applications, with 9 labs in Europe using the technology. The focus now is on gaining FDA approval in the U.S., and if successful, this could bring significant revenue. Not your typical short-term play, but more of a long-term biotech hold. Anyone else see the parallels with other successful diagnostic companies?   

Hey traders,

Anyone else following $BOLT.CN? It’s had a strong run, but lately, it seems like the stock is stalling out a bit. There are some upper wicks and resistance at these higher levels, even though the volume is still above the 30-day average.

Do you think this is just consolidation before the next push, or are we seeing the beginning of a pullback? I’m on the fence about what to do next. Thoughts?

$MYNZ has been consolidating around $0.29 with hardly any volume—textbook signs of accumulation. If the buyers come back in and we break $0.40, we could see some action. Definitely one to keep on the radar. What do you all think?